Table 1.
Expression of NVM-1 in human HCC and its clinical significance
| Characteristics | Cases | NVM-1 (negative) | NVM-1 (positive) | χ2 | P |
|---|---|---|---|---|---|
| Gender | 0.611 | 0.435 | |||
| Male | 80 | 37 (46.3%) | 43 (53.8%) | ||
| Female | 12 | 7 (58.3%) | 5 (41.7%) | ||
| Age (years) | 0.574 | 0.449 | |||
| < 60 | 78 | 36 (46.2%) | 42 (53.8%) | ||
| ≥ 60 | 14 | 8 (57.1%) | 6 (42.9%) | ||
| Hepatitis B | 2.343 | 0.126 | |||
| + | 82 | 42 (51.2%) | 40 (48.4%) | ||
| - | 10 | 2 (20.0%) | 8 (80.8%) | ||
| AFP (μg/L) | 1.093 | 0.296 | |||
| < 400 | 62 | 32 (51.6%) | 30 (48.4%) | ||
| ≥ 400 | 30 | 12 (40.0%) | 18 (60.0%) | ||
| Cirrhosis | 0.650 | 0.420 | |||
| Yes | 61 | 31 (50.8%) | 30 (49.2%) | ||
| No | 31 | 13 (41.9%) | 18 (58.1%) | ||
| Amount | 2.535 | 0.111 | |||
| = 1 | 66 | 35 (53.0%) | 31 (47.0%) | ||
| > 1 | 26 | 9 (34.6%) | 17 (65.4%) | ||
| Tumor size (cm) | 0.031 | 0.860 | |||
| ≤ 3.0 | 14 | 7 (50%) | 7 (50%) | ||
| > 3.0 | 78 | 37 (47.4%) | 41 (52.6%) | ||
| Tumor capsule | 0.565 | 0.452 | |||
| Yes | 58 | 26 (44.8%) | 32 (55.2%) | ||
| No | 34 | 18 (52.9%) | 16 (47.1%) | ||
| Differentiation | 19.723 | 0.000 | |||
| Well | 21 | 13 (61.9%) | 8 (38.1%) | ||
| Moderate | 43 | 27 (62.8%) | 16 (37.2%) | ||
| Poor | 28 | 4 (14.3%) | 24 (85.7%) | ||
| TNM stage | 5.808 | 0.016 | |||
| I+II | 69 | 38 (55.1%) | 31 (44.9%) | ||
| III+IV | 23 | 6 (26.1%) | 17 (73.9%) | ||
| BCLC stage | 8.445 | 0.015 | |||
| A | 58 | 34 (58.6%) | 24 (41.4%) | ||
| B | 12 | 5 (41.7%) | 7 (58.3%) | ||
| C | 22 | 5 (22.7%) | 17 (77.3%) | ||
| Metastasis* | 17.424 | 0.000 | |||
| No | 46 | 32 (69.6%) | 14 (30.40%) | ||
| Yes | 46 | 12 (26.1%) | 34 (73.9%) | ||
| Recurrencea | 11.127 | 0.001 | |||
| Yes | 53 | 18 (34.9%) | 35 (66.0%) | ||
| No | 34 | 24 (70.6%) | 10 (29.4%) | ||
| Recurrence time (months)a | 14.253 | 0.001 | |||
| < 6 | 36 | 9 (25.0%) | 27 (75.0%) | ||
| 6 ≤ X < 12 | 8 | 6 (75.0%) | 2 (25.0%) | ||
| ≥ 12 | 43 | 27 (62.8%) | 16 (37.2%) |
*
Metastasis was defined as recurrence time < 6 months or cancer embolus (including portal vein tumor thrombus, biliary tract tumor thrombus, and hepatic vein tumor thrombus).
a
Data are missing for 5 patients.